Director, President, and Chief Executive Officer · CATALYST PHARMACEUTICALS, INC. (CPRX)

Richard Daly

FY2024 is the first fiscal year CompBrief holds for Richard Daly as a named executive officer of CATALYST PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2024

$7,774,160

1st of 5 named executive officers at Catalyst Pharmaceuticals by FY2024 total.

5 named officers on file for CATALYST PHARMACEUTICALS, FY2024

See an example →

What this number hides

The filing gives the total. CATALYST PHARMACEUTICALS’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 11, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-07.

Free

Get Richard Daly’s full pay file as a PDF — free

More than this page: up to 10 years of Richard’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Richard Daly and every company like it: Velarion Intel, free for 3 days, no card →

Richard Daly compensation by year

CATALYST PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as CATALYST PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$750,000
Bonus$590,625
Stock awards$1,267,601
Option awards$5,070,830
Non-equity incentive$0
Pension and deferred compensation$0
All other$95,104
Total$7,774,160

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CATALYST PHARMACEUTICALS, INC. DEF 14A filed April 11, 2025, accession 0001193125-25-079097, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CATALYST PHARMACEUTICALS, INC. filed document, accession 0001193125-25-079097. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option491,160—$21.12
Option1,365,319—$13.30
Option5,000—$18.59

Per the Outstanding Equity Awards at Fiscal Year-End table in CATALYST PHARMACEUTICALS, INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

26 Form 4 lines since the FY2024 proxy (filed April 11, 2025)
current to 2026-11-07 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-07-15Disposition to the issuer derivative—115,283$0.000
2026-07-15Disposition to the issuer derivative—20,000$0.000
2026-07-15Disposition to the issuer derivative—40,013$0.000
2026-07-15Disposition to the issuer derivative—126,316$0.000
2026-07-15Disposition to the issuer—271,266$31.500
2026-07-15Disposition to the issuer derivative—33,500$0.000
2026-07-15Disposition to the issuer derivative—381,948$0.000
2026-07-15Disposition to the issuer derivative—1,365,319$0.000

The 8 most recent of 26 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

CATALYST PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Richard Daly · this pagePresident and CEO$7,774,160
Michael KalbEVP and CFO$6,180,936
Steven MillerCOO and CSO$3,545,774
Jeffrey Del CarmenCCO$2,638,127
Preethi SundaramChief Strategy Officer$2,528,555

Board service

CATALYST PHARMACEUTICALS board · FY2024

How this board is paid

Company policy: CATALYST PHARMACEUTICALS pays directors a $60,000 cash retainer and $300,019 in Stock options and RSUs. As stated in CATALYST PHARMACEUTICALS's FY2024 proxy.

The full CATALYST PHARMACEUTICALS compensation record

free company brief

This page is one person within CATALYST PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CATALYST PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CATALYST PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order CPRX

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Richard Daly's compensation dossier